SCHEMBL397242

SCHEMBL397242

Cc1c(C(=O)O)c(C)n(C(C(N)=O)N(C)C)c1C=C1C(=O)Nc2c(Nc3cccc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)c3)cccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 1/20 0.45
▸ BTK Q06187 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ NTRK1 P04629 3/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ SYK P43405 1/20 0.39
▸ NTRK2 Q16620 1/20 0.36
▸ TNIK Q9UKE5 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ ALK Q9UM73 1/20 0.36
▸ AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398145 0.94 RET (0.44) RETBTKKDM4EALDH1A1MAPT
SCHEMBL394153 0.90 RET (0.45) RETBTKKDM4EALDH1A1MAPT
SCHEMBL393783 0.88 RET (0.51) RETBTKKDM4EALDH1A1MAPT
SCHEMBL393048 0.86 RET (0.54) RETBTKNTRK1NTRK3ABL1
SCHEMBL396429 0.83 NTRK1 (0.40) ALDH1A1MAPTNTRK1NTRK3SRC
SCHEMBL4128689 0.82 RET (0.55) RETBTKKDM4EALDH1A1MAPT
SCHEMBL4128697 0.82 RET (0.55) RETBTKKDM4EALDH1A1MAPT
SCHEMBL395939 0.82 RET (0.49) RETBTKKDM4EALDH1A1MAPT
SCHEMBL395038 0.82 MAPK14 (0.38) NTRK1KDRFLT3AURKB
SCHEMBL398744 0.80 RET (0.53) RETBTKNTRK1NTRK3ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback